Abstract
The ability of an anti-TNF-alpha antibody to confer protection against enterohaemorrhagic Escherichia coli (EHEC) O157 was investigated in germfree IQI mice. The use of an antibiotic levofloxacin (LVFX) alone or with the antibody was also studied. Protection included an increase in survival rate. Treatment with the anti-TNF-alpha antibody inhibited the histological signs associated with EHEC infection but did not prevent the colonization of EHEC or production of Shiga toxin (Stx). No clinical signs were observed and EHEC was completely eliminated in the mouse model receiving both anti-TNF-alpha antibody and LVFX. Anti-TNF-alpha antibody suppressed inflammatory cytokine response in the mouse kidney and brain by EHEC infection.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Infective Agents / pharmacology
-
Anti-Infective Agents / therapeutic use*
-
Antibodies, Bacterial
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Disease Models, Animal
-
Escherichia coli Infections / drug therapy*
-
Escherichia coli Infections / microbiology
-
Escherichia coli O157 / drug effects*
-
Escherichia coli O157 / metabolism
-
Female
-
Germ-Free Life
-
Immunoglobulin G / pharmacology
-
Immunoglobulin G / therapeutic use
-
Kidney / pathology
-
Levofloxacin*
-
Male
-
Mice
-
Ofloxacin / pharmacology
-
Ofloxacin / therapeutic use*
-
Shiga Toxin / biosynthesis
-
Survival Analysis
-
Time Factors
-
Tumor Necrosis Factor-alpha / immunology*
Substances
-
Anti-Infective Agents
-
Antibodies, Bacterial
-
Antibodies, Monoclonal
-
Immunoglobulin G
-
Tumor Necrosis Factor-alpha
-
Levofloxacin
-
Shiga Toxin
-
Ofloxacin